INMB - Inmune Bio, Inc.
IEX Last Trade
4.72
0.020 0.424%
Share volume: 2,585
Last Updated: Thu 26 Dec 2024 08:30:11 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$4.70
0.02
0.43%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-02 | 2023-03-02 | 2023-05-03 | 2023-08-07 | 2023-11-01 | 2024-03-28 | 2024-05-09 | 2024-08-01 | |
| Total revenue | 98.000 K | 97.000 K | 38.000 K | 46.000 K | 43.000 K | 28.000 K | 14.000 K | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 98.000 K | 97.000 K | 38.000 K | 46.000 K | 43.000 K | 28.000 K | 14.000 K | 0.000 | |
| -1.02% | -60.82% | 21.05% | -6.52% | -34.88% | -50.00% | -100.00% | |||
| Operating expenses | 7.541 M | 5.739 M | 6.461 M | 6.457 M | 8.571 M | 8.407 M | 11.031 M | 9.865 M | |
| Selling general and admin | 2.382 M | 2.329 M | 2.328 M | 2.309 M | 2.586 M | 2.400 M | 2.338 M | 2.812 M | |
| Research and development | 5.159 M | 3.410 M | 4.133 M | 4.148 M | 5.985 M | 6.007 M | 8.693 M | 7.053 M | |
| Total expenses | 7.541 M | 5.739 M | 6.461 M | 6.457 M | 8.571 M | 8.407 M | 11.031 M | 9.865 M | |
| -23.90% | 12.58% | -0.06% | 32.74% | -1.91% | 31.21% | -10.57% | |||
| Operating income | -7.443 M | -5.642 M | -6.423 M | -6.411 M | -8.528 M | -8.379 M | -11.017 M | -9.865 M | |
| Ebit | -7.443 M | -5.642 M | -6.423 M | -6.411 M | -8.528 M | -8.379 M | -11.017 M | -9.865 M | |
| Pretax income | -7.725 M | -5.833 M | -6.536 M | -6.501 M | -8.563 M | -8.408 M | -11.025 M | -9.746 M | |
| -24.49% | 12.05% | -0.54% | 31.72% | -1.81% | 31.13% | -11.60% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -7.725 M | -5.833 M | -6.536 M | -6.501 M | -8.563 M | -8.408 M | -11.025 M | -9.746 M | |
| 24.49% | -12.05% | 0.54% | -31.72% | 1.81% | -31.13% | 11.60% | |||
| Net income | -7.725 M | -5.833 M | -6.536 M | -6.501 M | -8.563 M | -8.408 M | -11.025 M | -9.746 M | |
| 24.49% | -12.05% | 0.54% | -31.72% | 1.81% | -31.13% | 11.60% |